Literature DB >> 32765803

Uveal Melanoma and Kidney Cancer: More Similar than Meets the Eye.

Nirmish Singla1.   

Abstract

Entities:  

Keywords:  BAP1; chromosome 3; clear cell renal cell carcinoma; prognosis; treatment; uveal melanoma

Year:  2020        PMID： 32765803      PMCID： PMC7405959     

Source DB:  PubMed          Journal:  Kidney Cancer J        ISSN： 1933-0863


× No keyword cloud information.
  5 in total

1.  Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.

Authors:  Anshuman Panda; Aguirre A de Cubas; Mark Stein; Gregory Riedlinger; Joshua Kra; Tina Mayer; Christof C Smith; Benjamin G Vincent; Jonathan S Serody; Kathryn E Beckermann; Shridar Ganesan; Gyan Bhanot; W Kimryn Rathmell
Journal:  JCI Insight       Date:  2018-08-23

2.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

3.  Molecular genetics of clear-cell renal cell carcinoma.

Authors:  James Brugarolas
Journal:  J Clin Oncol       Date:  2014-05-12       Impact factor: 44.544

4.  Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival.

Authors:  Manuel Rodrigues; Khadija Ait Rais; Flore Salviat; Nathalie Algret; Fatoumata Simaga; Raymond Barnhill; Sophie Gardrat; Vincent Servois; Pascale Mariani; Sophie Piperno-Neumann; Sergio Roman-Roman; Olivier Delattre; Nathalie Cassoux; Alexia Savignoni; Marc-Henri Stern; Gaëlle Pierron
Journal:  JAMA Ophthalmol       Date:  2020-02-01       Impact factor: 7.389

5.  Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma.

Authors:  Marc Ladanyi; Francisco Sanchez Vega; Marjorie Zauderer
Journal:  Genome Med       Date:  2019-03-26       Impact factor: 11.117
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.